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Abstract
Background: Central serous chorioretinopathy is a disorder often related to systemic corticosteroids, drugs
commonly used in rheumatologists’ clinical practice. Central serous chorioretinopathy prognosis is generally
good but in some cases, it may lead to substantial loss of vision resulting in an important functional limitation
for patients.
It is very important to distinguish this pathology from other diseases involving retinal detachment. When central
serous chorioretinopathy and uveitis coexist, it is mandatory to distinguish serous retinal detachment from a uveitis
worsening, as the respective treatments can be radically different.
Case presentation: We describe three cases of central serous chorioretinopathy in patients taking systemic
corticosteroids due to rheumatological diseases (ankylosing spondylitis, systemic lupus erythematosus and
Behçet’s disease). They were diagnosed and managed at our Multidisciplinary (Rheumatology-Ophthalmology)
Uveitis Clinic. All three cases improved after corticosteroids dose tapering.
Conclusion: Central serous chorioretinopathy must be kept in mind by rheumatologists as it is related to
systemic corticosteroids.
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Background
Central serous chorioretinopathy (CSCR) is a disease
characterized by serous detachment of the neurosensory
retina and/or the retinal pigment epithelium (RPE).
The most accepted physiopathologic mechanism is
the leakage of vascular fluid through a focal leak in
the RPE into the subretinal space as a consequence of
choroidal vessel hyperpermeability.
When the macula is affected, CSCR results in blurred
vision, metamorphopsia and micropsia.
CSCR predominantly affects middle-aged adults.
Several risk factors have been described, the most
recognized ones being: type-A personality and psycho-
logical stress [1, 2], pregnancy [3], and increased
levels of corticosteroids of exogenous and endogenous
origin [4–10].
Although CSCR prognosis is generally good, this ill-
ness often affects the macula leading to a loss of visual
acuity (VA) and resulting in an important functional
limitation for patients.
Furthermore, when not diagnosed and treated cor-
rectly, CSCR can become chronic leading to diffuse
damage of the RPE, permanent loss of VA, and compli-
cations involving choroidal neovascularization.
Herein we describe three cases of CSCR diagnosed
and managed at our Uveitis Clinic.
Case presentation
Case 1
A 45-year-old man diagnosed with HLA B27 positive
ankylosing spondylitis. During the follow up in our
department, the patient showed axial and peripheral
articular involvement and suffered several episodes of
anterior acute uveitis in the right eye. He was treated
with NSAIDs and methotrexate 15 mg/week p.o.
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In December 2012 the patient developed a new acute
anterior uveitis episode on the right eye, which was di-
agnosed and initially managed in another medical cen-
ter. He was treated with prednisone 60 mg/day after
topical and periocular corticosteroid injection failure.
While on this treatment, the patient was referred to
our consulting room. We found no inflammatory signs
on the anterior chamber by ophthalmological examin-
ation (uveitis episode had been resolved) but the patient
kept complaining about blurred vision. Funduscopic
examination showed a retinal detachment which was
confirmed and characterized as CSCR by optical coher-
ence tomography (OCT).
Because of the absence of inflammatory signs and the
possible association of CSCR with systemic corticother-
apy, we decided to decrease the prednisone dose until
full discontinuation leading to resolution of the retinal
detachment.
Four months after prednisone discontinuation the pa-
tient developed a new uveitis episode which was treated
with periocular triamcinolone injection, to which adali-
mumab 40 mg EOW was added due to the aggressive
course even under methotrexate treatment. With this
combined treatment, the patient has not had any recur-
rences until the present day, and treatment with sys-
temic corticosteroids has not been necessary.
Case 2
A 37-year-old woman with a history of sigma adenocar-
cinoma treated with surgery. She was diagnosed with
systemic lupus erythematosus (SLE) with hematological,
renal, articular and serous involvement. The following
treatment was initiated: methotrexate 5 mg/week P.O. and
prednisone 7.5 mg/day, as well as rituximab 375 mg/m2
104 weekly × 4 (off label use) only upon relapse. Previously
she had been treated with chloroquine, but it had to be
suspended as the patient developed an antimalarial related
maculopathy.
In June 2013 the patient was referred to our consulting
office because of blurred vision of new onset. The previ-
ous month she had suffered an SLE relapse (pleuritis
and deterioration of renal function in a context of lupus
glomerulonephritis class III) that was treated with a new
cycle of rituximab and prednisone 60 mg/day. On fun-
duscopic examination, a retinal detachment was ob-
served which was confirmed by autofluorescence and
OCT (see Figs. 1 and 2).
A differential diagnosis between serous retinal detach-
ment (SRD) related to SLE [11, 12] and corticosteroid-
related CSCR was considered. We decided that the
corticosteroid-related CSCR option was more reasonable
because of an absence of ocular inflammatory changes and
the good response to treatment of the previous SLE re-
lapse, as well as finding no other clinical or analitical signs
of SLE activity. Thus, we initiated a prednisone dose taper-
ing until 5 mg/day, which led to the CSCR resolution.
Three months later the patient suffered a new relapse
of SLE (pleuritis), so a new rituximab cycle was adminis-
tered, thereby avoiding systemic corticosteroids except
for a single dose of endovenous metilprednisolone
100 mg as rituximab premedication. The SLE relapse
was resolved and the patient hasn’t had new ocular in-
volvement until the present day.
Case 3
A 45-year-old man with a history of recurrent pan-
creatitis of enolic etiology. He was diagnosed with
Behçet’s disease with both mucous (oral and genital
ulcers) and ocular involvement (bilateral papillitis and
cystoid macular edema). The following treatment was
initiated: cyclosporine 200 mg/day P.O. and prednis-
one (doses ranging from 5 mg/day to 60 mg/day de-
pending on disease activity), as well as rituximab
1000 mg EOW × 2 (off label use) only upon relapse.
Previously he had been treated with infliximab but
had to be discontinued due to an infusion reaction.
In April 2012, the patient was referred to our consult-
ing room because of blurred vision.
Funduscopic examination and OCT revealed bilateral
vitritis as well as SRD. The patient was on treatment with
cyclosporine 200 mg/day P.O. and prednisone 5 mg/day.
As inflammatory signs were detected in addition to the
SRD, we decided to add a new cycle of rituximab. This
treatment led to vitritis resolution but SRD persisted on
both eyes. At this point, we considered that the SRD could
be related to chronic use of systemic corticosteroids, so
we decided to decrease the prednisone dose to 2.5 mg
EOD, not adding any other immunosuppressant drug.
Initially, SRD was resolved, but seven months later
he suffered a new episode of uveitis on the left eye
(papilitis, vitritis, and cystoid macular edema). A sub-
tenon injection of triamcinolone 40 mg and a new
cycle of rituximab were initiated. Systemic corticoste-
roids were avoided, with exception of an endovenous
metilprednisolone 100 mg premedication prior to
rituximab infusion. Following this latest treatment, in-
flammatory signs disappeared and no SRD has been
detected until the present day.
Discussion
CSCR is a disease that must be kept in mind by rheuma-
tologists, as it is a relatively frequent disorder [13] re-
lated to systemic corticosteroids, drugs commonly used
in our clinical practice.
It is also important to have a fluid communication
with ophthalmologists, who must do a good differential
diagnosis with other diseases associated with retinal
detachment such as: Vogt Koyanagi Harada, myopia,
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diabetes mellitus and central retinal vein thrombosis, as
well as diseases that can have a similar course of action
such as chronic CSCR (which like age-related macular
degeneration, should be suspected in elder patients).
This is very important, as treatment of these diseases
can be radically different: the initial treatment for cor-
ticosteroid related CSCR should be corticoids with-
drawal, what would worsen the course of inflammatory
chorioretinopathies.
In the event of CSCR and uveitis coexistence, as in
our first and third cases, it is mandatory to distinguish
serous retinal detachment from uveitis worsening, as
the symptomatology can be very similar [14]. For this
reason, an optimal ophthalmological examination is
necessary, as well as the use of additional diagnostic
tools such as OCT, autofluorescence and fluorescein
angiography [15]. When CSCR is diagnosed in a context
of previous or concomitant uveitis, immunosuppressants
other than corticosteroids should be initiated, or previous
immunosuppressants doses increased. When corticoste-
roids cannot be avoided because of emergency or limited
access to other drugs, topical or periocular forms should
be employed.
A limitation of our approach to these cases is that we
didn’t consider other risk factors for CSCR development.
Nonetheless, as systemic corticosteroids use is the better
one described, we considered this risk factor as the most
probably related to CSCR in our cases. Another possible
limitation of this report is the absence of additional
studies including fluorescein and ICG angiography as
well as some examination technologies (adaptive optics,
electroretinography, microperimetry, or contrast sensi-
tivity testing) for the diagnosis and especially for the
patients’ follow-up, as it is described that these tech-
nologies can detect subclinical damage [15].
Conclusions
CSCR must be kept in mind by rheumatologists as it
is related to systemic corticosteroids, drugs commonly
used in our daily practice.
In the event of CSCR and uveitis coexistence, it is
mandatory to distinguish serous retinal detachment from
uveitis worsening.
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Fig. 2 Left-eye optical coherence tomography images of case 2. a Serous retinal detachment (arrows). b Resolution of fluid collection after
discontinuation of oral steroids
Fig. 1 Autofluorescence images of case 2. a, b Multifocal central serous choroidopathy is shown in both eyes (arrows)
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